Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Operations (2016 - 2025)

Assembly Biosciences has reported Cash from Operations over the past 11 years, most recently at 14237000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 14237000.0 for Q4 2025, up 3598.03% from a year ago — trailing twelve months through Dec 2025 was 41093000.0 (up 19.61% YoY), and the annual figure for FY2025 was 41093000.0, up 19.61%.
  • Cash from Operations for Q4 2025 was 14237000.0 at Assembly Biosciences, up from 15133000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for ASMB hit a ceiling of 73647000.0 in Q4 2023 and a floor of 33344000.0 in Q1 2021.
  • Median Cash from Operations over the past 5 years was 18124500.0 (2022), compared with a mean of 12366300.0.
  • Biggest five-year swings in Cash from Operations: tumbled 277.36% in 2021 and later skyrocketed 3598.03% in 2025.
  • Assembly Biosciences' Cash from Operations stood at 19362000.0 in 2021, then increased by 0.56% to 19254000.0 in 2022, then soared by 482.5% to 73647000.0 in 2023, then tumbled by 100.55% to 407000.0 in 2024, then skyrocketed by 3598.03% to 14237000.0 in 2025.
  • The last three reported values for Cash from Operations were 14237000.0 (Q4 2025), 15133000.0 (Q3 2025), and 16758000.0 (Q2 2025) per Business Quant data.